Patrick D. Yeramian is Chief Medical Officer at Amylyx Pharmaceuticals, Inc. (AMLX). They have made 2 open-market trades across 1 company since 2023, most recently 2024-01-09.
CIK 0001358266
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AMLX | 205,605 | $5.4M |
Shares reported on the most recent Form 4, priced at the 2024-01-11 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AMLX | SELL | 2024-01-09 | 2024-01-11 | $16.33 | $46K | -10.6% | +1.1% | -84.7% |
| AMLX | SELL · 10b5-1 | 2023-05-15 | 2023-05-17 | $29.03 | $695K | -13.8% | -14.4% | -24.7% |
| AMLX | SELL · 10b5-1 | 2023-04-17 | 2023-04-19 | $30.53 | $3.0M | -8.0% | -13.8% | -27.9% |
| AMLX | SELL | 2023-03-16 | 2023-03-24 | $31.88 | $3.5M | -3.9% | +4.7% | -14.4% |
| AMLX | SELL · 10b5-1 | 2023-01-06 | 2023-01-10 | $36.30 | $74K | +5.3% | -6.6% | -19.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.